Oruka Therapeutics (ORKA) Cash from Financing Activities (2010 - 2026)

Oruka Therapeutics' Cash from Financing Activities history runs 14 years deep, the most recent figure standing at $40.6 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities changed N/A year-over-year to $40.6 million; the TTM figure through Mar 2026 stood at $210.3 million (changed N/A YoY), while the FY2025 annual figure was $170.3 million, down 62.11% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $40.6 million, up from $298000.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $423.7 million in Q3 2024, with the low at -$1.6 million in Q2 2024.
• The 3-year median for Cash from Financing Activities is $27.9 million (2024), against an average of $94.3 million.
• Peak annual rise in Cash from Financing Activities reached 156.65% in 2025, while the deepest fall reached 59.9% in 2025.
• Oruka Therapeutics' Cash from Financing Activities stood at -$526000.0 in 2024, then soared by 156.65% to $298000.0 in 2025, then soared by 13524.16% to $40.6 million in 2026.
• Business Quant data shows ORKA's Cash from Financing Activities at $40.6 million in Q1 2026, $298000.0 in Q4 2025, and $169.9 million in Q3 2025.